|
FATE | Fate Therapeutics Inc |
|
|
FATE | Fate Therapeutics Inc |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 0.63 |
| Leverage | 41.01% |
| Market Cap | $ 243.1m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -125.6m |
| Margin | -894.61% |
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders globally. The company is headquartered in San Diego, California.